LEXARIA BIOSCIENCE CORP reports a Return on Equity (ROE) of -163.18%.

What is LEXX's dividend yield?

LEXARIA BIOSCIENCE CORP offers a dividend yield of 0.00%.

What is LEXX's Quality Score?

Our AI rates LEXX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy LEXX?

Our AI Timing Score for LEXX is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does LEXX belong to?

LEXARIA BIOSCIENCE CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

LEXX (NASDAQ) Stock Analysis | LEXARIA BIOSCIENCE CORP

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-05-31)

LEXX AI Analysis Summary

Our AI summary for LEXX: LEXARIA BIOSCIENCE CORP (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -163.18%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LEXX

LEXARIA BIOSCIENCE CORP

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 0.39

-0.01 (-1.34%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-163.2%

ROE

-161.7%

ROA

0.00%

Div Yield

LEXARIA BIOSCIENCE CORP
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.39 Price -0.01 (-1.34%) Day Change	NEWS SCORE: 98

LEXX, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.39
PBV / Sector	2.26 / 5.20
Earning Per Share	-0.31

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	0.06 M GREAT
Average 1W Daily Value	0.12 M GREAT

Timing Factors

14%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-3,985.58 / 98.71
NPM Average (%) / Sector	-2,542.49 / -1,721.76
NPM Change Average (%) / Sector	29.34 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-161.71 / 27.02
ROA Average (%) / Sector	-164.21 / -368.17
ROA Change Average (%) / Sector	89.02 / 5,404.12 GREAT
ROE (%) / Sector	-163.18 / 3.47
ROE Average (%) / Sector	-188.76 / 6.51
ROE Change Average (%) / Sector	116.34 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:06
Symbol	LEXX
Name	LEXARIA BIOSCIENCE CORP
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	24.79 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	9.82 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7

Phone: 250 765 6424

Website: https://lexariabioscience.com

Sector: Healthcare >> Biotechnology

Description: Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.